I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The way I look at it is that if someone else already had the catalyst, wouldn't it make sense that they would be using it in a P2O operation at least on a small scale demonstration somewhere?
This is right up your alley. Enjoy...
http://www.forbes.com/free_forbes/2010/0426/investing-pink-sheets-fraud-stock-scam-madoff-spot-pump-dump.html?partner=yahoomag
Here is ITRO 's big pump.
http://www.moneytv.net/frontpage.htm
Just watch Dr. John Whitney dazzle them with his hypnotic voice. LOL
$H - Could you please help Doc write up a rebuttal to the recent Forbes article? Doc needs to sign up with Forbes and explain his side of the story and give an update on the current situation not a couple of years old P&D. The sooner the better so that everyone who reads the article can also see the rebuttal. This could actually benefit ITRO with the Forbes exposure when they read the recent progress. Maybe even get a retraction or a follow-up article.
http://www.forbes.com/free_forbes/2010/0426/investing-pink-sheets-fraud-stock-scam-madoff-spot-pump-dump_2.html
Big Cat Energy Provides Coal Bed Methane Operators Proposals Exceeding $11 million To Manage CBM / CSNG Produced Water, In-Bo...
Date : 04/13/2010 @ 9:15AM
Source : Business Wire
Stock : Big Cat Energy Corporation (BCTE)
Quote : 0.13 0.0 (0.00%) @ 8:19AM
Big Cat Energy Provides Coal Bed Methane Operators Proposals Exceeding $11 million To Manage CBM / CSNG Produced Water, In-Bo...
Big Cat Energy Corporation (www.bigcatenergy.com) (“Big Cat”) (BCTE: OTCBB), a supplier of the ARID® Aquifer Recharge Injection system, today provided an operational update on its current operations.
Big Cat has received requests for proposals from seven major coal bed methane (CBM/CSNG) operators in Wyoming and Montana. The proposals represent $11 million of potential revenue to the Company and encompass approximately 580 well sites. “We are encouraged by the interest in the ARID systems shown by these operators,” said Tim Barritt, Big Cat CEO and President. “With the tight margin on gas prices and the increased pressure to eliminate surface discharge, the use of ARID in-bore aquifer recharge at around $0.03 per barrel is the intelligent choice for CBM water management,” added Mr. Barritt. “Acceptance of any of Big Cat’s proposals would substantially increase the Company’s sales and cash flow.”
The ARID In-bore Aquifer Recharge Injection System has been selected as the water handling component for a proof of concept project to enhance the public water supply in the Southwestern United States. The project team includes, among others, a major university and a US Federal Agency. The first phase of this project is scheduled to be completed in September 2010 and will have a budget of $40 million. The project involves the collection and re-injection of a combined solution of treated brine water and drinking water into existing drinking water aquifers to enhance and preserve the public drinking water supply for future use. “The positive outcome of this project will have an enormous impact on Big Cat’s long term revenue stream,” noted Ray Murphy, Big Cat’s Geologist and Chief Operating Officer.
Big Cat is in discussions with a service provider in Australia to evaluate the use of the ARID System for handling Coal Seam Natural Gas produced water in Australia prior to major CSNG development in that Country. “We are currently researching the potential for this new market and believe there is a large opportunity for Big Cat in Australia that must be attacked while CSNG Operators are searching for economical and environmentally friendly water handling solutions,” said Mr. Barritt.
"We are also involved in a research project with another CBM operator utilizing a federal grant rejuvenating small producer involvement in CBM by demonstrating the economic impact of utilizing development best practices. This study will use results of the salvage process to create an economic model connecting costs of salvaging within the value of the proved reserves, and book previously abandoned reserves as proven reserves,” noted Mr. Barritt.
If final contracts are achieved, fulfillment of the above proposals and new business opportunities may require additional working capital. The Company is currently exploring potential financing options, including private placement and debt opportunities, to provide for the Company’s future cash flow requirements.
About Big Cat Energy Corporation
Big Cat Energy Corporation works with Coal Bed Methane (“CBM”) Well operators to assist them in implementing the most cost effective, yet most environmentally friendly, method for handling produced water. Big Cat Energy Corporation’s ARID Aquifer Recharge Injection System and Service allows CBM operators to save money by re-injecting the water produced from their CBM gas wells, eliminating surface discharge, and retaining usable water for the landowners future needs.
For sales information contact Jim Farnsworth or Tim Barritt at 307-468-9369 or email sales@bigcatenergy.com, or visit our web site at http://www.bigcatenergy.com
Investor Relations
Tel: (877) 912-2283
Email: investor@bigcatenergy.com
Web: www.livecallir.com
Forward-Looking Statements
Portions of this document may constitute "forward-looking statements" as defined by federal law. Although the Company believes any such statements are based on reasonable assumptions, there is no assurance that actual outcomes will not be materially different. Any such statements are made in reliance on the "safe harbor" protections provided under the Private Securities Reform Act of 1995. Additional information about issues that could lead to material changes in performance is contained in the Company's annual reports filed with the Securities and Exchange Commission.
True - but they seemed to be happy to trade it tic by tic until it hit $5.50. It's ok because it would be better to build up over several days than to go parabolic and then a huge retract.
MM's throwing in the towel? Don't have any more to sell? ASK went to $6.45? Looks like a huge spread to kill the rally before it breaks resistance?
You can only swim against the current for so long. You have now reached the base of Niagara Falls. Time to admit futility, turn around and go with the flow.
Thanks $H for clearing up another false statement. I would not be surprised if who ever sold today did so on this false claim.
Please ($H) correct me if I am wrong but we are looking at increased in efficiency and 10x more production soon with 100x current production to follow later. ITRO currently has .04 percent of the market and we are looking at grabbing 4 percent with the 100x expansion.
So your saying that Coke started out as a scam and then turned into a multi-billion operation and this is why we should not invest in JBII?
Interesting Point...
Mr Swing send out an email update on NNVC...
http://www.mrswing.com/articles/NNVC_chart_update_1.html
Another 52 week high and with good volume too.
I saw the down trend coming and thought about selling but decided to ride it out for now. I might add if it can hold this range for a while. Lots of irons in the fire right now and never know which ones will get hot first. I continue to believe in the long-term growth here so I try not to let the "tic by tic" distract me.
I don't think it would take 3 weeks if that was all they were going to say.
Clay - Would you please post a chart on JBII and give your technical opinion? Thanks
So are 27 of 47 3DEO's installed in Hispanics grocery stores? And if they are, is the company earning the estimated rev's for each installed unit (rev's listed below must be estimated given the fact that only one retailer had any of them installed)?
Thanks
What size shoe do you wear? LOL
Thanks. I appreciate it.
Headed in the right direction :)
Acro, Inc. Receives Purchase Order for Explosive Detection Devices From Division of U.S. Army
Date : 04/06/2010 @ 6:11PM
Source : MarketWire
Stock : Acro, Inc. (ACRI)
Quote : 0.0399 0.0097 (32.12%) @ 8:10AM
Acro, Inc. Receives Purchase Order for Explosive Detection Devices From Division of U.S. Army
CAESAREA, ISRAEL -- (Marketwire)
04/06/10
Acro, Inc. (OTCBB: ACRI), a leading manufacturer of explosive detection solutions for the homeland security market and related sectors, today announced that the Company has received a purchase order for its ACRO-P.E.T., ACRO-N.E.T., ACRO-CH.E.T., and ACRO-U.E.T. explosive detection devices from a division of the U.S. Army.
"This order is very important for us because it continues our momentum in the United States and could further increase market adoption of our cutting-edge explosive detection solutions," said Gadi Aner, CEO and Chairman of Acro, Inc.
The ACRO-P.E.T. is the first explosives identifier of its kind, effective against TATP and other Peroxide Based IEDs. It is light, easy to use and gives instant results, even when explosive quantities are small. The novel portable 'micro-laboratory,' ACRO-N.E.T., with its sensitive, simple, rapid, precise and reliable operation, revolutionizes the field task of police and other security agencies in the detection and identification of explosives. ACRO-CH.E.T. (Chlorate Explosives Tester) is light, easy to use and gives instant results, even when explosive quantities are small. ACRO-CH.E.T. has low false positive and negative alarm rates, is very sensitive, and can detect 10 micrograms of chlorate based explosives traces.
This initial purchase order will be used to determine the suitability of Acro's explosive detection devices for certain U.S. Army units. The order is expected to ship within few weeks.
About Acro:
Acro, Inc. develops explosives detection technologies and manufactures relevant products. In addition to the explosives detectors that are currently marketed by Acro, the company continues to develop proprietary technologies for the HLS market. Acro's Advisory Board includes Nobel Prize laureate Prof. K. Barry Sharpless, and Prof. Richard A. Lerner, President and CEO of The Scripps Research Institute, one of the most influential scientific institutes worldwide. For more information about Acro, visit www.AcroSec.com.
Forward-Looking Statement
This press release contains forward-looking statements concerning our marketing and operations plans. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. All forward-looking statements in this press release are made based on management's current expectations and estimates, which involve risks, uncertainties and other factors that could cause results to differ materially from those expressed in forward-looking statements. These statements involve a number of risks and uncertainties including, but not limited to, risks related to the evolving homeland security market, general economic conditions and other risk factors. Acro does not undertake any obligation to update forward-looking statements made herein.
For more information please contact
Acro, Inc.
info@AcroSec.com
BIOLASE Announces Presentation of Its Technology to National Meeting of Eye Surgeons
Date : 04/06/2010 @ 6:00AM
Source : MarketWire
Stock : BIOLASE Technology, Inc. (BLTI)
Quote : 2.04 0.02 (0.99%) @ 7:22AM
BIOLASE Announces Presentation of Its Technology to National Meeting of Eye Surgeons
IRVINE, CA -- (Marketwire) 04/06/10
BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, today announced that a presentation this week at a national meeting of eye surgeons will cover the multiple benefits and promising potential applications that its newest water-based laser technologies have for eye surgery.
Erin Stahl, M.D., a pediatric and refractive surgeon at Children's Mercy Hospital in Kansas City, will present a comprehensive paper, outlining benefits such as minimal pain and the prevention of the flow of bleeding, or hemostasis, to the American Society of Cataract and Refractive Surgery Symposium and Congress in Boston, Massachusetts.
In her paper titled "The Use of a Novel, Water-Based Laser to Cut and Coagulate Anterior Segment Tissue," Dr. Stahl concluded that BIOLASE's water-based laser technology now well accepted in dentistry "has the potential to be a multipurpose cutting tool that could be used across disciplines" in eye surgery. The multiple ophthalmic applications for the BIOLASE laser technology include presbyopia, plastic surgery, glaucoma, strabismus (the abnormal alignment of the eyes) and anterior segment/sclera.
Dr. Stahl noted that, in general, there are similarities to the uses of water-based laser technologies in dentistry and eye surgery in part because the tissues in the mouth are very similar to those on and around the eye. Dr. Stahl has investigated using a YSGG Waterlase Laser created by BIOLASE to cut various ocular tissues in a laboratory setting.
"The water-based laser device has been very successful in dentistry because it can cut hard and soft tissue and has a unique way of cutting, with low inflammation and a lack of bleeding," Dr. Stahl said. "That may translate into a variety of potential uses for ophthalmology for such things as bone sculpting and tissue dissection with hemostatis for plastic surgery, angle surgery for glaucoma, and scleral incisions for relaxing procedures or implant placement."
The presentation was accompanied by a video provided by Jose Maria Rodriguez, M.D., an ophthalmologic surgeon at Hospital Ramon Y Caial in Madrid, Spain. Dr. Rodriguez is a global leader in experimenting with lasers in eye surgery.
BIOLASE has developed a variety of water-based dental laser systems as well as the FDA-cleared OCCULASE MD? Laser System, developed specifically for general ophthalmic soft tissue surgical applications including presbyopia, or the inability to focus on near objects, typically due to aging. Presbyopia affects a majority of adults over the age of 40.
Dr. Stahl is the daughter of Daniel S. Durrie, M.D., a member of the BIOLASE Board of Directors. She has no personal financial interest in the Company.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, develops, manufactures and markets Waterlase technology and lasers and related products that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with reduced pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology, pain management and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact: Jill Bertotti (investor) and Len Hall (media), of Allen & Caron, +1-949-474-4300.
MESOBLAST'S MARKET EXCLUSIVITY FOR ITS BIOLOGIC PRODUCTS STRENGTHENED BY NEW UNITED STATES HEALTH CARE ACT
O Key provision in new United States Patient Protection and Affordable Care Act provides a biologic innovator such as Mesoblast with 12 years of exclusive market protection from date of biologic product approval
O Modifying the structure of the biologic product to improve safety, purity, or potency may result in further 12 years of market exclusivity
O As biologic innovators, Mesoblast and its United States-associate company Angioblast Systems, are well positioned to significantly extend the period of United States commercial exclusivity for their cell therapy products well beyond initial patent expiration dates
O This materially increases long-term revenue projections for both companies
Melbourne, Australia; 6 April 2010: Australian regenerative medicine company and biologic innovator, Mesoblast Limited (ASX:MSB; ADR:MBLTY), today provided an assessment on how the recently enacted United States Patient Protection and Affordable Care Act (HB 3590) is expected to have a positive impact on the commercial prospects for both Mesoblast and its United States-associated company, Angioblast Systems Inc.
The assessment indicates that the Act will facilitate a material increase in the long-term revenue projections for both companies for their biologic products in the United States, the world's largest market for regenerative medicines. Of particular relevance to both companies is a key provision in the Act, which provides a biologic innovator with long-term exclusive market protection of its approved product against abbreviated approval of biosimilar biologic products by the United States Food and Drug Administration (FDA).
A biosimilar product is deemed to be interchangeable with an already approved reference biologic based upon highly similar analytical studies, and clinical trials that demonstrate safety, purity and potency for the same indication. The Act explicitly prohibits FDA approval of a biosimilar until 12 years after the date on which the reference biologic product is first approved. It further stipulates an additional 6 months of exclusivity for the use of reference biologic products in the paediatric population. In addition, under the Act the innovator may receive a further 12 years of exclusivity from the date of approval of any subsequent biologic product which has a structure that has been modified to result in a change in safety, purity, or potency of the reference biologic.
Maintaining commercial exclusivity for its biologic products through a robust international patent portfolio is fundamental to Mesoblast's commercial strategies. The United States Patent and Trademark Office has already granted Mesoblast and Angioblast key composition-of-matter and manufacturing patents for their innovative cell therapy products. These patents provide exclusive commercial protection for the companies' reference biologic products in the United States through to at least 2019, with potential for significant patent life extension. Additional patents have been filed covering specific uses of the companies' biologic products that considerably extend the duration of patent protection. The new provisions for biosimilar biological products within the Patient Protection and Health Care Affordability Act, which was signed into law 23 March 2010, now provides both Mesoblast and Angioblast with the potential to significantly extend commercial exclusivity for their cell therapy products in the United States well beyond initial patent expiration dates. This will serve to significantly increase long-term revenue projections for both companies, and to facilitate their strategic business partnerships.
About Mesoblast
Mesoblast Limited (ASX:MSB;ADR:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.
www.mesoblast.com
For further information, please contact:
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61 (03) 9639 6036
M: +61 (0) 419 228 128
E: julie.meldrum@mesoblast.com
W: www.mesoblast.com
also see:
http://www.abnnewswire.net/press/en/62558/
It is their loss... Unless I see something that concerns me, this is a loooong term hold so I'm not too concerned about the chart or the buzz on other boards. Too illiquid to trade so when you buy here you are married for a while.
Yes - twice - and asked someone else to request it also but don't know if they did.
Update to Question #5
JB: With question #5 I sent the message without completing it. She left the company in July 2009. We have a strict policy that family cannot work for JBI so when we decided to have a relationship, she left.
I appreciate your Q&A efforts and I did not mean to jump the gun but I sent JB some questions on FB and he has already responded and said I could post them...
I will not add anything or change any of John's words but I will cut and paste them to each question.
1) How many shares of JBII did Gregory Goldberg own before joining JBII?
JB:1. The same as in the 8k and form 4 (I think it was 65,000?)
2) Is Mr. Goldgerg's past connections with an off-shore shorting hedge fund a concern (detractors are speculating that he could facilitate insiders shorting against JBII's restricted stock)?
JB:2. Not at all. I want that expertise here. I do believe people should understand that shorting is not a concern here. We execute - they bleed. Really simple. As well, DTC supplies reports that show what market makers are short of delivering and how much. There is little shorting here. The market seems to understand that we aren't predicable and I will or can cause a number of events to force a cover.
3) How many large P2O processors does JBII currently own? How many have been ordered?
JB:3. Three. Two built (one large, one mobile), one being built.
4) On the JV with 45 P2O sites, are there time frames that must me met or the agreement is void (if yes then are we on track to deliver within the agreement)?
JB:4. No
5) What is Lynn Bordynuik's ( EA to CEO ) salary/compensation?
JB:5. Lynn is not an EA and had not worked for the company since . When we had a relationship she left the company and payroll. She receives no compensation. She does act as my assistant (for free) and this does help the company as she understands many aspects of what we do. Christine Merrick is my EA and I can't disclose what she is being paid but it is not 6 figures.
6) After you generously returned the shares for super voting rights, the OS shares numbers ended up being approximately 2 million higher than expected, can you please explain the discrepancy?
JB:6. Yes, the TA failed to issue the shares for the asset purchase and some debt conversion. As well, some stock I returned to the treasury was issued to new officers and key people to encourage them to join JBI and have a stake in its success. We relied on their numbers when reporting the outstanding amounts. The number of shares were adjusted when we reconciled the PIPE shares with the TA printouts.
Few notes (just so that there isn't any misconceptions):
#1) We do not need to order any future processors from China. We built two processors here. Some shareholders have seen our mobile 1T unit work.
#2) We have substantially changed the original machine, credit islechem for the optimization. You will see it at the AGM.
My understanding is that JB will have a Q&A following the Islechem reports and before the AGM.
They tossed out the (struggling) business that they had and now all hope is in the "magic beans" of EEstor. I will keep watching but looking for something more concrete before I buy. Of course if good news from EEstor does come out it will probably jump quite quickly. Hard to figure the EEstor Story. They are not trying to scam anyone (except maybe ZENN?). But if they could deliver, I would think that they would at least be showing off a prototype zipping around even if you could not look under the hood.
Thanks for clearing that up.
I told you so... LOL
This board is dead but the stock is alive.
He has posted on this board a few times after his resignation and I did not see anything that he said that would concern me.
It was in the newest 8k filing. Also John SR is a shareholder according to what I found in the filings (under 5% so you might have to dig to figure it out). Most small shareholders in the tape business cashed out and JB did sell a small portion when the tape business was sold to JBII. Even though the PPS was considerably lower then it still would have given JB some cash to live on for a while. No secret but you have to read the filings from early last year.
Here is some interesting RZ data...
http://www.mffais.com/rz
FB - John Bordynuik - Very bad internet connection here (2kb/sec) so I will respond to questions when I get back. I have 30 hours of travel coming up. My presentation. Went really well and I spoke about tapes and p2o. Was interviewed by national tv for p2o. Big problem everywhere and we have the only solution (nice). Can't wait to get back.... It is very challenging here. Had to use my phone for this - no int/landline
Give me the numbers and I'll check for you - lol
Any update from the "field" on BCTE?
Looks like consolidation is almost over and then up to the next level.
Looks like the "News" players are gone (along with the volume). Let's see if it can hold above .04
I'm too think that it is only a matter of time before value is "found" here.